Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that Dr. Mark Pykett, Neoprobe’s President and Chief Executive Officer, will deliver a presentation to institutional investors at 3:15 PM ET, Monday, September 12, 2011 at the Rodman & Renshaw Annual Global Investment Conference, taking place at The Waldorf-Astoria, New York. Investors and the public are invited to listen to a live webcast of Dr. Pykett’s presentation at http://www.wsw.com/webcast/rrshq20/neop. An archived edition of the presentation will be available for 30 days following the presentation. About Neoprobe Neoprobe Corporation (NYSE Amex: NEOP) is a biomedical company focused on enhancing oncology patient care and improving patient benefit through radiopharmaceutical product development. Neoprobe is actively developing two radiopharmaceutical agent platforms – Lymphoseek® and RIGScanTM CR – to help surgeons better identify and treat certain types of cancer. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline program through continued investment and selective acquisitions. For more information, please visit www.neoprobe.com.
Shares of Neoprobe Corporation (AMEX:NEOP) were gapping up Thursday morning with an open price 17.9% higher than Wednesday's closing price. The stock closed at $2.63 yesterday and opened today's trading at $3.10.